Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
“Repare Therapeutics (RPTX) is a busted biotech with a liquidation value of at least $2/share (possibly more, could be some IP value), but nothing really notable has changed since my write-up last month. One slight positive, they did include a new line in their 10-Q making the strategic review more clear, from the MD&A section: "We plan to explore a full range of strategic alternatives and partnerships across our portfolio to maximize shareholder value." BSD Analysis: Repare Therapeutics Inc. (RPTX) Repare is a precision oncology play dedicated to the high-potential field of Synthetic Lethality, a genomic strategy that targets cancer cells by exploiting specific DNA repair deficiencies. The investment thesis centers on its proprietary SNIPRx® platform for identifying novel drug targets, particularly its lead program lunresertib in combination with a WEE1 inhibitor, with a Phase 1 readout expected later in 2025. The company's high valuation is justified by the massive, multi-megablockbuster potential of its platform if any of its pipeline candidates show definitive clinical efficacy and superior durability in patients with difficult-to-treat tumors. This is a platform technology bet, meaning success in one asset could instantly validate the entire portfolio and drive a massive re-rating or M&A interest.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
